Progress under GAP Pillar 2 "Increase Production Capacity" Contribution of the WHO Technology Transfer Programme. Martin Friede
|
|
|
- Alexandra Wood
- 5 years ago
- Views:
Transcription
1 Progress under GAP Pillar 2 "Increase Production Capacity" Contribution of the WHO Technology Transfer Programme Martin Friede
2 Global influenza vaccine production capacity since 2006 Cantacuzino Romania Torlak Serbia RIBSP RIBSP Kazakstan Kazakhstan RAZI Iran Razi Institute Iran BCHT China Green Cross Rep of Korea Birmex Mexico Vacsera Egypt SII India GPO Thailand IVAC Vietnam Instituto Butantan Brazil BioFarma Indonesia Countries with GAP projects Biovac South Africa Countries with influenza vaccine production capacity in 2006 Countries with first influenza vaccine registered between 2006 and 2012 Countries with planned influenza vaccine production capacity The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. WHO All rights reserved. Countries with planned influenza vaccine fill-finish capacity 2
3 Overall progress 2006-now Korea, India, Brazil, Thailand, Romania pandemic vaccines approved or clinical trials completed Current capacity: 320 million doses annually. Remaining challenges: Ensure antigen sparing technology optimised Ensure continued NRA approval Nine others; Significant progress: facilities, process, clinical trials Need to ensure that momentum is not lost. Predicted additional capacity : 300 million 3
4 Highlights 2012 Grants to 14 recipients managed, technical assistance and training provided and progress monitored LAIV technology now licensed to 3 manufacturers 1 product prequalified Enhanced generation and supply of LAIV seed strains 1 IIV seasonal vaccine approved 2 clinical trials supported 9 Assessment visits conducted 4
5 Progress and status of grantees BCHT (China) License to LAIV negotiated Building started Biovac Negotiation of bulk supply completed, Filling line ordered ; Birmex Fill-finish facility nearly completed. Local bulk manufacturer already producing bulk 5
6 Biofarma (indonesia) Pilot H5N1 lots produced, adjuvant lots produced. Facility for local antigen production under construction Butantan (Brazil) Approval of seasonal tiiv split vaccine by NRA Capacity: 20 M SH, 10M NH Adjuvant technology: pandemic capacity 120M doses 6
7 Cantacuzino (Romania) Completion of building, installation of upgraded filling line. Adjuvant lots completed IVAC (Vietnam) H1N1 phase 1 trial completed H5N1 consistency lots completed. GPO (Thailand) H5N2 LAIV phase 1 trial completed H5N2 LAIV phase 2 trial initiated. Facility for IIV started. 7
8 RAZI (Iran) Review of technologies suitable for local production Negotiation for access to technology initiated RIBSP (Kazakhstan) National funds secured for building large-scale facility Technologies compared and selected SII (India) Prequalification of plaiv H1N1 Efficacy trials of H1N1 vaccine completed Phase III Efficacy trial of seasonal tlaiv underway in infants 8
9 Torlak (Serbia) Buildings completed and validated Consistency lots (whole inactivated) completed Implementing change to split. Vacsera (Egypt) Preclinical lots / immunogenicity Production facility under construction 9
10 WHO Technology Transfer Initiative QSS WIPO IVR TAG TTi HIP GAP MoH RO, WR 10
11 Technology Transfer activities Direct assistance Grants, access to technologies Technical advice, TAG, consultants, meetings with MoH,.. To assist vaccine manufacturer sustainability Technology assessment, IP analysis, investment analysis Facilitate negotiation with technology owners Access to cell lines, strains, SOPs, reagents Influenza and other vaccines Other biological technologies: potential to increase sustainability of influenza production 11
12 Conclusions A lot of progress has been made >300 million pandemic vaccine capacity already. A lot still needs to be made Another 300 million to be brought on line. Most infrastructure investments completed. Now need to focus on reaching approval and sustainability Challenges Which technology for seasonal and pandemic? Approval pathway for pandemic 12
Outline. World Health Organization 14 July, Strengthening for capacity to regulate influenza vaccines
Strengthening for capacity to regulate influenza vaccines Outline WHO reorganization and Regulatory Systems Strengthening (RSS) Team WHO Regulatory Systems Strengthening Department of Essential Medicines
Approaches to Pandemic Influenza Vaccine Preparedness
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Approaches to Pandemic Influenza Vaccine Preparedness Julie Schafer, MPH, MS Influenza
The RIVM as knowledge and training centre
The RIVM as knowledge and training centre Belgrade, Serbia March 2012 Marit Holleman 1 Content: 1. Training and Technology Transfer at RIVM 2. Training on influenza vaccines 3. New courses 2 Training and
Biomanufacturing Training and Education Center (BTEC) s International Influenza Vaccine Manufacturing Training Program
Biomanufacturing Training and Education Center (BTEC) s International Influenza Vaccine Manufacturing Training Program 5 th Meeting with International Partners on Prospects for Influenza Vaccine Manufacturing
Influenza Vaccine Innovation
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Influenza Vaccine Innovation New Vaccines Approved and on the Way Rick A. Bright, Ph.D.
NVI Experience and Concept of Central Technology Hub
NVI Experience and Concept of Central Technology Hub Jan Hendriks Netherlands Vaccine Institute (NVI) MSF/Oxfam Consultation improving access and stimulating vaccine development for use in resource pour
How to successfully get a Flu Vaccination Policy accepted and implemented? the Thai experience
How to successfully get a Flu Vaccination Policy accepted and implemented? the Thai experience WHEII, June 5 th, 2012, Intercontinental Hotel, Bali, Indonesia Dr. Suwit Wibulpolprasert Senior Advisor on
Meeting with international partners on influenza vaccine production technology transfer to developing countries
WHO/IVB/10.10 ORIGINAL: ENGLISH Meeting with international partners on influenza vaccine production technology transfer to developing countries 5-6 May 2010, Nha Trang, Viet Nam Immunization, Vaccines
Jan Hendriks & Claire Boog Netherlands Vaccine Institute (NVI)
Influenza Technology Hub a WHO Vaccinology Centre of Excellence Bilthoven, the Netherlands WHO Technology Transfer Workshop 30 November-1 December 2010 Jan Hendriks & Claire Boog Netherlands Vaccine Institute
Request for Letters of Intent. International Development of H5N1 Influenza Vaccines
Request for Letters of Intent International Development of H5N1 Influenza Vaccines The World Health Organization (WHO) intends to provide funding to developing (1) country vaccine manufacturers to develop
XDR-TB Extensively Drug-Resistant Tuberculosis. What, Where, How and Action Steps
XDR-TB Extensively Drug-Resistant Tuberculosis What, Where, How and Action Steps The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever
Vaccine Development in the Developing World; past, present and future: SEAR Perspective
Speech by Dr Samlee Plianbangchang Regional Director, WHO South-East Asia Vaccine Development in the Developing World; past, present and future: SEAR Perspective 15 June 2010 Bangkok, Thailand Vaccine
The Vaccine Formulation Laboratory
FIFTH MEETING WITH INTERNATIONAL PARTNERS ON PROSPECTS FOR INFLUENZA VACCINE TECHNOLOGY TRANSFER TO DEVELOPING COUNTRY VACCINE MANUFACTURERS The Vaccine Formulation Laboratory Adjuvant Hub & Training Center
CANCER FACT SHEETS: BREAST CANCER
CANCER FACT SHEETS: BREAST CANCER Estimated age-standardised rates (World) in the world (per 100 000) At a glance WHO South-East Asia Region More developed regions WHO African Region WHO Region of the
Towards a Sustainable Global Infrastructure for Medical Countermeasures
Towards a Sustainable Global Infrastructure for Medical Countermeasures Institute of Medicine The Public Health Emergency Medical Countermeasures Enterprise: Innovative Strategies to Enhance Products from
Report of the Fifth Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine
Report of the Fifth Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Manufacturers Belgrade, Serbia, 27-28 March 2012 WHO Library
The Global Action Plan to increase supply of pandemic influenza vaccines
WHO/IVB/10.08 ORIGINAL: ENGLISH The Global Action Plan to increase supply of pandemic influenza vaccines Report of the fourth meeting of the WHO Global Action Plan of the Advisory Group Nha Trang, Viet
The epidemiology of tuberculosis
The epidemiology of tuberculosis Tuberculosis Workshop Shanghai, 12-22 May 28 Philippe Glaziou World Health Organization Outline Epidemiology refresher Estimates of tuberculosis disease burden Notifications
Update on A(H1N1) pandemic and seasonal vaccine availability. July 7, 2009
Update on A(H1N1) pandemic and seasonal vaccine availability July 7, 2009 Presentation objectives and approach Presentation Objectives Review production status for 2009-2010 Northern Hemisphere vaccine
Quality assurance for essential medicines and health products: moving towards an harmonized approach
Quality assurance for essential medicines and health products: moving towards an harmonized approach Prequalification of vaccines David Wood QSS/EMP/WHO 12 December 2012 A growing portion of vaccines procured
Market Updates: Routine Vaccine Introductions IPV. Vaccine Industry Consultation October 2018 UNICEF Supply Division
Market Updates: Routine Vaccine Introductions IPV Vaccine Industry Consultation October 2018 UNICEF Supply Division Outline Review of rapid introduction of IPV Overview of the current situation for 2018
2. Treatment coverage: 3. Quality of care: 1. Access to diagnostic services:
The theme for World TB Day 2014 is Reach the missed 3 million. Every year 3 million people who fall ill with TB are missed by health systems and do not always get the TB services that they need and deserve.
Expedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines
Expedited procedure for evaluating pandemic influenza A (H1N1) 2009 vaccines Preamble On 11 June 2009, WHO declared an influenza pandemic caused by influenza A (H1N1) 2009 virus 1. On 13 July 2009, WHO
Vaccine Preventable Disease Surveillance: Overview. Thomas Cherian, WHO
Vaccine Preventable Disease Surveillance: Overview Thomas Cherian, WHO Global Framework on Immunization Monitoring and Surveillance (GFIMS) l An extension of the GIVS, published on December 07 - http://www.who.int/immunization/en/
Vaccine Production and Regulation
Vaccine Production and Regulation Dr Houda LANGAR Essential Vaccines and Biologicals Policy Department of Health Systems & Services Development Capacity Development Workshop on Health System Development
WHO Rotavirus Vaccine Update Dr. Fatima Serhan WHO/FWC/IVB/EPI
WHO Rotavirus Vaccine Update 2012 Dr. Fatima Serhan WHO/FWC/IVB/EPI WHO estimates that 453 000 child deaths occurred during 2008 due to rotavirus infection 41057 32653 39144 98621 82% of these deaths occurred
Drug resistance TB in People Living with HIV: research questions and priorities.
Drug resistance TB in People Living with HIV: research questions and priorities. Haileyesus Getahun, MD, PhD. Stop TB Department World Health Organisation Geneva, Switzerland Outline of presentation Definition
Update on polio vaccine supply & forecast
Update on polio vaccine supply & forecast DCVMN - Polio Vaccines Session 27 September 2017 UNICEF/UNI199159/Panday Ian Lewis, UNICEF Supply Division Overview of presentation bopv supply situation and outcome
Michel BAIJOT Vice President, WW Business Development & Strategic Alliances
Technology Transfer and Vaccines: The GSK Experience WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Geneva, November 30th, 2010 Michel BAIJOT Vice President, WW Business
Current Situation on Avian Influenza and the pandemic threat
Vaccine-preventable diseases and Immunization, Communicable Diseases Surveillance and Response Current Situation on Avian Influenza and the pandemic threat IVth Joint EC/ECDC/WHO Workshop on Pandemic Influenza
CANCER FACT SHEETS: LIVER CANCER
CANCER FACT SHEETS: LIVER CANCER Estimated age-standardised rates (World) in the world (per 100 000) At a glance China WHO Western Pacific Region Less developed regions World WHO African Region United
CANCER FACT SHEETS: ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER
CANCER FACT SHEETS: ALL CANCERS EXCLUDING NON-MELANOMA SKIN CANCER Estimated age-standardised rates (World) in the world (per 100 000) At a glance United States of America European Union (EU-28) More developed
Second intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network
Summary report on the Second intercountry meeting on the Eastern Mediterranean Acute Respiratory Infection Surveillance (EMARIS) network WHO-EM/CSR/070/E Sharm el-sheikh, Egypt 24 27 November 2013 Summary
What can be done against XDR-TB?
What can be done against XDR-TB? Dr Matteo Zignol Stop TB Dep. World Health Organization Geneva 16 th Swiss Symposium on tuberculosis Münchenwiler, 22 March 2007 XDR-TB Extensive Drug Resistance XDR =
Update on influenza maternal immunization. Joachim Hombach WHO Initiative for Vaccine Research
Update on influenza maternal immunization Joachim Hombach WHO Initiative for Vaccine Research Influenza Burden of Disease WHO global estimate: 3-5 million severe cases, 250 000 500 000 deaths
How and Why Vaccines Are Developed by Industry. Stanley A. Plotkin
How and Why Vaccines Are Developed by Industry Stanley A. Plotkin Merieux 2012 1 Why Vaccines are Different than Drugs 1) Given to healthy people, high safety required 2) Larger governmental role 3) Low
The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps
The WHO Global Project on anti-tb drug resistance surveillance: background, objectives, achievements, challenges, next steps Matteo Zignol STOP TB Department World Health Organization TB surveillance and
Regional Overview of the implementation of National Control Strategies for Avian Influenza. Summary review of questionnaire OIE RRAP
Regional Overview of the implementation of National Control Strategies for Avian Influenza Summary review of questionnaire OIE RRAP The OIE Questionnaire on Influenza A surveillance in animals in the Asia
CANCER FACT SHEETS: STOMACH CANCER
CANCER FACT SHEETS: STOMACH CANCER Estimated age-standardised rates (World) in the world (per 100 000) At a glance WHO Western Pacific Region China Less developed regions World More developed regions IARC
Feasibility of Production of Human AI Vaccine in AI vaccine Manufacturers in China. Gu Hong Ministry of Agriculture of P. R. China
Feasibility of Production of Human AI Vaccine in AI vaccine Manufacturers in China Gu Hong Ministry of Agriculture of P. R. China AI -- common challenge to the all countries Global cooperation in control
Outline. Role of Developing Country Vaccine Industry For Meeting Global Vaccine Needs. Immunization Landscape ADVAC 2013
Role of Developing Country Vaccine Industry For Meeting Global Vaccine Needs ADVAC 2013 Dr. Suresh Jadhav Executive Director Serum Institute of Limited Maharashtra,, 411028 ssj@seruminstitute.com France,
WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA
WHO REGIONAL OFFICE FOR EUROPE RECOMMENDATIONS ON INFLUENZA September 2017 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for Europe Marmorvej
XDR and MDR TB Urgent Research Priorities. Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine
XDR and MDR TB Urgent Research Priorities Gerald Friedland MD Yale School of Medicine Nelson R Mandela School of Medicine The Year of MDR XDR TB CDC, WHO report on global XDR TB XDR TB defined Global distribution
RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE WINTER SEASON
RECOMMENDATIONS ON INFLUENZA VACCINATION DURING THE 2018 2019 WINTER SEASON October 2018 Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional Office for
Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch
Objective 2 Strengthening Routine Immunization, IPV introduction and the topv-bopv switch Polio Partners Group meeting Geneva 8 December 2014 Michel Zaffran Coordinator, WHO/EPI, IMG Co-chair On behalf
REGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC. second edition
REGIONAL ALLIANCE FOR NATIONAL REGULATORY AUTHORITIES FOR VACCINES IN THE WESTERN PACIFIC second edition World Health Organization 2014 The designations employed and the presentation of the material in
Conflict of Interest and Disclosures. Research funding from GSK, Biofire
Pandemic Influenza Suchitra Rao, MBBS, Assistant Professor, Pediatric Infectious Diseases, Hospital Medicine and Epidemiology Global Health and Disasters Course, 2018 Conflict of Interest and Disclosures
Ensuring quality, safety and efficacy of vaccines
EDCTP Third Annual Forum 2006 Partnership and African Leadership: Challenges & Opportunities Ensuring quality, safety and efficacy of vaccines Vaccine regulatory issues in African countries Lahouari Belgharbi,
MAPS ON GLOBAL TOBACCO CONTROL POLICY DATA
APPENDIX XII: MAPS ON GLOBAL TOBACCO CONTROL POLICY DATA Appendix XII provides global overview maps on monitoring tobacco prevalence, smoke-free environments, treatment of tobacco dependence, health warnings
Maternal and Neonatal Tetanus Elimination by Yes, We Can! Global Immunization Meeting 18 th February 2009
Maternal and Neonatal Tetanus Elimination by 2012 Yes, We Can! Global Immunization Meeting 18 th February 2009 OUTLINE Can we eliminate MNT by 2012? Can MNTE contribute to MDG4? Can TT-SIAs help to deliver
Recommended composition of influenza virus vaccines for use in the 2007 influenza season
Recommended composition of influenza virus vaccines for use in the 2007 influenza season September 2006 This recommendation relates to the composition of vaccines for the forthcoming winter in the southern
WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES
WHO GLOBAL ACTION PLAN FOR INFLUENZA VACCINES SURVEY QUESTIONNAIRE A.1. Introduction The Global Action Plan for Influenza Vaccines (GAP) was launched in 2006 as a ten year initiative to address the anticipated
DCVMN AND VACCINE SECURITY IN ASEAN REGION. ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014.
DCVMN AND VACCINE SECURITY IN ASEAN REGION ASEAN Countries on Opportunities for Regional Vaccine Security 1-3 October, 2014. Phuket - Thailand Developing Countries Vaccine Manufacturers Network (DCVMN)
Vaccinating Against the Pandemic H1N1 Influenza Virus. Background. Milestones in Influenza Vaccine Development. Increased Safety, Less Reactogenicity
Vaccinating Against the Pandemic H1N1 Influenza Virus Background Alvin Nelson El Amin, MD, MPH Medical Director Immunization Program Milestones in Influenza Vaccine Development Isolation of the influenza
Report of the Ninth Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine
Report of the Ninth Meeting with International Partners on Prospects for Influenza Vaccine Technology Transfer to Developing Country Vaccine Manufacturers Geneva, Switzerland, 17 November 2016 Ordering
Global progress in vaccine development
Global progress in vaccine development Helen McShane The Jenner Institute University of Oxford helen.mcshane@ndm.ox.ac.uk Vaccination The most cost-effective health intervention Smallpox Poliomyelitis
Establishing human vaccine manufacturing in Southern Africa
Engineering Conferences International ECI Digital Archives Vaccine Technology IV Proceedings Spring 5-21-2012 Establishing human vaccine manufacturing in Southern Africa Morena Makhoana The Biovac Institue
DEVELOPMENT AND PRODUCTION OF INFLUENZA VACCINES INSTITUTO BUTANTAN PROF. ISAIAS RAW JANUARY 2013
DEVELOPMENT AND PRODUCTION OF INFLUENZA VACCINES INSTITUTO BUTANTAN PROF. ISAIAS RAW JANUARY 2013 BUTANTAN: GOALS AS A PUBLIC INSTITUTE, THE GOAL OF BUTANTAN IS TO PRODUCE EFFICACIOUS AND SAFE VACCINES
Pandemic H1N Dr. Maria Neira Global Influenza Programme WHO, Geneva
Pandemic H1N1 2010 Dr. Maria Neira Global Influenza Programme WHO, Geneva WHO Role during pandemic (H1N1) 2009 Under the International Health Regulations (2005) Detect event (notification by Member States
Assessment of Influenza Vaccine Production Compatibilities
United States Department of Health & Human Services Office of the Assistant Secretary for Preparedness and Response Assessment of Influenza Vaccine Production Compatibilities Joshua Speidel, PhD Influenza
Summaries of Complementary Presentations on Agenda Item:
Summaries of Complementary Presentations on Agenda Item: WHO s Role in Supporting Emerging Vaccine Manufacturers To inform the SAGE discussion on this agenda item, four presentations have been solicited
Procedure for Expedited Review of imported pre-qualified vaccines for use in national immunization programmes
Procedure for Expedited Review of imported pre-qualified vaccines for use in national immunization programmes Dr Nora Dellepiane/Dr Anil Kumar Chawla WHO/HQ-Geneva, Switzerland 1 Expedited review procedure
Table 1. Measles case classification and incidence by country and area, WHO Western Pacific Region,
Volume 7 Issue 5 May 2013 ISSN 1814 3601 Table 1. case classification and by country and area, WHO Western Pacific Region, 2008 2013 1 confirmed 2 2 009 per confirmed 2 2 010 2 011 2 012 2013 1 Confirmed
Financing Influenza Vaccine R&D
Financing Influenza Vaccine R&D WHO GAP-II Geneve, Switzerland July 13, 2011 Robin Robinson, Ph.D. Deputy Assistant Secretary & Director HHS/ASPR/BARDA 0 Vaccine Development is Risky, Lengthy, & Expensive
Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine. since 2006
Industry Perspective: Strategies and costs associated with increasing seasonal influenza vaccine use from high to low income countries since 2006 Dr. Michael Watson, sanofi-pasteur on behalf of WHO GAP
The State of Measles and Rubella in the WHO European Region
The State of Measles and Rubella in the WHO European Region Mark Muscat Vaccine-preventable Diseases and Immunization Rome, Italy, 16-17 June 2016 All six WHO Regions have measles elimination goals 2 Annual
GSK s Adjuvanted Influenza Vaccines The Taming of the Flu
GSK s Adjuvanted Influenza Vaccines The Taming of the Flu JITMM, Bangkok, October 2008 Bruce L. Innis, MD Global Clinical Research and Development GlaxoSmithKline Biologicals 1 Annual Burden of Influenza
Overall presentation of IVR Strategy
Annex 3 Overall presentation of IVR Strategy Presentation to the IVR Advisory committee (IVAC) April 2007 Outline Why does WHO invest in Research & Development? What is the Initiative for Vaccine Research
Regulatory Capacity Building and Developing Countries: CBER Perspective
Regulatory Capacity Building and Developing Countries: CBER Perspective Karen Midthun, M.D. Director Center for Biologics Evaluation and Research US Food and Drug Administration IOM Meeting Strengthening
FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA
Comprehensive Family Immunization Family and Community Health Area FINAL RECOMMENDATIONS ON PANDEMIC INFLUENZA TECHNICAL ADVISORY GROUP ON VACCINE-PREVENTABLE DISEASES 24-26 AUGUST 2009, COSTA RICA Epidemiological
Executive Summary. Final version_29 Sept 2014 Page 1
Executive Summary Final version_29 Sept 2014 Page 1 WHO consultation on influenza vaccines for pregnant and lactating women: Clinical data requirements for product labelling 15 16 July 2014 Geneva, Switzerland
Public health relevant virological features of Influenza A(H7N9) causing human infection in China
Public health relevant virological features of Influenza A(H7N9) causing human infection in China Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional
New Delhi International Ministerial Conference on Avian and Pandemic Influenza Dec 4-6th, 2007
New Delhi International Ministerial Conference on Avian and Pandemic Influenza Dec 4-6th, 2007 Session IV Influenza Pandemic Preparedness Dr Paul R Gully Health Security and Environment, Geneva Avian Influenza
3.1 PHASE 2 OF THE GLOBAL PROJECT
RESULTS CHAPTER 3 3.1 PHASE 2 OF THE GLOBAL PROJECT (1996 1999) This new report of the Global Project provides data on anti-tuberculosis drug resistance from 58 geographical settings. Of these, 28 provided
HPV Vaccination Global policy perspectives Vacuna VPH Perspectivas de la política de vacunación mundial
HPV Vaccination Global policy perspectives Vacuna VPH Perspectivas de la política de vacunación mundial 1 Paul Bloem EPI Team WHO IVB Geneva Outline HPV disease burden, vaccines and WHO recommendations
Update on Polio Vaccine Supply
Update on Polio Vaccine Supply Vaccine Industry Consultation 6 th October 2017 UNICEF/UNI199159/Panday Ian Lewis and Andisheh Ghazieh, UNICEF Supply Division Outline IPV update on supply and demand bopv
Regulatory Preparedness for Human Pandemic Influenza Vaccines
EXPERT COMMITTEE ON BIOLOGICAL STANDARDIZATION Geneva - 8 to 12 October 2007 ENGLISH ONLY FINAL Version endorsed by ECBS Proposed Guidelines: Regulatory Preparedness for Human Pandemic Influenza Vaccines
Ethics Perspective of Immunisation Programs
Ethics Perspective of Immunisation Programs with special reference to Herd Effect T Jacob John Vellore, India Annecy 26 October 2010 Defining Herd immunity and Herd effect. Between participants and nonparticipants
Technology Transfer from the Perspective of IFPMA vaccine members
Technology Transfer from the Perspective of IFPMA vaccine members WHO Workshop on Technology Transfer for Local Manufacturing Capacity of Vaccines Michael Watson (Sanofi Pasteur) Chair of IFPMA Biologicals
Measles and Rubella Global Update SAGE 19 October 2017
Measles and Rubella Global Update SAGE 19 October 2017 Alya Dabbagh WHO HQ, IVB/EPI Global update Overview Regional progress and challenges M&RI Midterm Review updates Economics of measles and rubella
Developing a novel Group B Streptococcus (GBS) Vaccine. Patrick Tippoo
Developing a novel Group B Streptococcus (GBS) Vaccine Patrick Tippoo Presentation 1. Overview of Biovac 2. GBS Project Overview 3. African Significance Biovac Overview A Centre of Excellence rooted in
Review of Avian Influenza A(H5N1) for WHO SAGE
Review of Avian Influenza A(H5N1) for WHO SAGE SAGE Geneva November 2013 Joseph Bresee, MD Epidemiology and Prevention Branch Influenza Division National Center for Immunization and Respiratory Diseases
Development of polysaccharide-based conjugate vaccine against Haemophilus influenzaetype b infection
Development of polysaccharide-based conjugate vaccine against Haemophilus influenzaetype b infection Adriansjah A. Bio Farma, Indonesia May 15 2007 Haemophilus influenzae Gram-negative, coccobacillus bacterium
Pandemic Influenza Preparedness Framework. Sharing influenza viruses & access to vaccines and other benefits
Pandemic Influenza Preparedness Framework Sharing influenza viruses & access to vaccines and other benefits What is PIP? Landmark, innovative public health arrangement to increase global preparedness to
Hepatitis B vaccination worldwide: Lessons learnt and the way forward
Hepatitis B vaccination worldwide: Lessons learnt and the way forward VHPB Russia meeting Oct 2018 Pierre Van Damme MD, PhD History Hepatitis B vaccines have been available since early 1980 s First recommended
Current needs for Vaccine R & D and Implementation in Developing Countries : Norwegian & Intl. Partners Contribution
Current needs for Vaccine R & D and Implementation in Developing Countries : Norwegian & Intl. Partners Contribution by DR.SURESH S. JADHAV Executive Director Serum Institute of India Ltd/Pune & President
Measles and Rubella Global Update SAGE April 2018
Measles and Rubella Global Update SAGE April 2018 Alya Dabbagh WHO HQ, IVB/EPI Overview Global update Regional update Surveillance overview M&RI Midterm Review updates Conclusions 2 Measles and Rubella
7/30/2017. One World Medical Physics: Challenges and Opportunities in Cancer Care. Worldwide Demographic Shift
People 60 Years and Older ( in Millions) 7/30/2017 One World Medical Physics: Challenges and Opportunities in Cancer Care Jatinder R Palta PhD, FAAPM, FASTRO, FACR Virginia Commonwealth University, and
Jinchang Wu, Ph.D. Director of International Affairs, Changchun BCHT March, 2013 Dubai
Jinchang Wu, Ph.D. Director of International Affairs, Changchun BCHT March, 2013 Dubai Established in March 2004 at Changchun High-tech Zone, Jilin Province, Northeast China Research, development, production
Alternative Rotavirus Vaccine Candidates: Why should we bother?
Alternative Rotavirus Vaccine Candidates: Why should we bother? Duncan Steele Initiative for Vaccine Research, WHO 7 th International Rotavirus Symposium 12-13 June 2006, Lisboa, Portugal Rotavirus Vaccines
FAOAIDEnews Animal Influenza Disease Emergency
FAOAIDEnews Animal Influenza Disease Emergency Situation Update 82 17 November 2011 HPAI outbreaks reported in this publication refer to officially confirmed cases only. The information is compiled from
Human H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry
Human H5N1 and Pandemic Vaccines Practicalities of Production: A perspective from Industry Luc Hessel M.D. Pandemic Influenza Working Group European Vaccine Manufacturers 4th Joint EC/ECDC/WHO Workshop
Column chromatography for the development of pandemic and seasonal influenza vaccines
Column chromatography for the development of pandemic and seasonal influenza vaccines Olga Chervyakova Research Institute for Biological Safety Problems, RK ME&S 5 th Meeting with International Partners
Intellectual Property Rights & Vaccines in Developing Countries
Intellectual Property Rights & Vaccines in Developing Countries by Dr. S.S.Jadhav President DCVMN Developing Country Vaccine Manufacturers Network DCVMN Formed in November 2000. 7 members steering committee.
Pandemic Influenza Preparedness and Response
24 th Meeting of Ministers of Health Dhaka, Bangladesh, 20-21 August 2006 SEA/HMM/Meet.24/4(b) 10 July 2006 Pandemic Influenza Preparedness and Response Regional situation: Human cases and outbreaks of
Influenza. Influenza vaccines (WHO position paper) Weekly Epid. Record (2005, 80: ) 287
Program Management 82_19 SAGE encouraged all countries to consider their preparedness for a potential influenza pandemic, recognizing that it would occur before strain-specific vaccine can be made in significant
Dr Laszlo Palkonyay World Health Organization
International Proficiency Study of the Single Radial Immuno Diffusion Test (SRID) for Influenza Vaccine Manufacturers and Regulators from Developing Countries Dr Laszlo Palkonyay World Health Organization
The Gates Challenge. Bill Gates Commencement Address Harvard University Class of 2007
History & Future of the Expanded Programme on Immunization Supplier Meeting, Copenhagen, 3-4 April 2008 Dr Osman David Mansoor Senior Adviser EPI (New Vaccines) UNICEF New York The Gates Challenge If we
Current Trends in ODS Production and Supply
6 5 4 3 2 1 1995 1997 1999 21 23 25 27 29 Current Trends in ODS Production and Supply Erik Pedersen Tenth Annual Financial Agents Workshop The World Bank Washington, D.C. June 27 to June 28, 26 Apparent
Christian Gunneberg MO WHO The 14th Core Group Meeting of the TB/HIV Working Group November 11-12, 2008, Addis Ababa, Ethiopia
The revised TB/HIV indicators and update on the process of harmonization Christian Gunneberg MO WHO The 14th Core Group Meeting of the TB/HIV Working Group November 11-12, 2008, Addis Ababa, Ethiopia Monitoring